Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3214-3224

  Aranda, Fernando ^a   Llopiz, Diana ^a   Díaz Valdés, Nancy ^a   Riezu Boj, José Ignacio ^a   Bezunartea, Jaione ^a   Ruiz, Marta ^a   Martínez, Marta ^a   Durantez, Maika ^a   Mansilla, Cristina ^a   Prieto, Jesús ^a   Lasarte, Juan José ^a   Borrás Cuesta, Francisco ^a   Sarobe, Pablo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CD40 ANTIBODY; IMIQUIMOD; MELANOMA ANTIGEN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; IMMUNOGENICITY; INNATE IMMUNITY; MELANOMA; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; ANTIGENS, CD4; ANTIGENS, NEOPLASM; FEMALE; IMMUNITY, INNATE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OVALBUMIN; POLY I-C; T-LYMPHOCYTES; THYMOMA; TRANSFECTION;

EID: 79955488983     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3259     Document Type: Article

References (39)

1. Finn OJ. Cancer immunology. N Engl J Med 2008;358:2704-15.
2. Smith ME, Marsh SG, Bodmer JG, Gelsthorpe K, Bodmer WF. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci U S A 1989;86: 5557-61. (Pubitemid 19185583)
3. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 2008;20:504-11.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52. (Pubitemid 28155090)
5. Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res 2007;67:7945-7. (Pubitemid 47395122)
6. Cho HI, Celis E. Optimized peptide vaccines eliciting extensive CD8 Tcell responses with therapeutic antitumor effects. Cancer Res 2009;69:9012-9.
7. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004;199:775-84. Epub 2004 Mar 8. (Pubitemid 38375197)
8. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-76. (Pubitemid 43090462)
9. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006;108:544-50. (Pubitemid 44061354)
10. Ouyang X, Negishi H, Takeda R, Fujita Y, Taniguchi T, Honda K. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem Biophys Res Commun 2007;354:1045-51. (Pubitemid 46216241)
11. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, et al. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A 2008;105:16260-5.
12. Llopiz D, Dotor J, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, et al. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects. Cancer Immunol Immunother 2008;57:19-29. (Pubitemid 350043645)
13. Fidler IJ. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 1975;35:218-24.
14. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996;184:465-72. (Pubitemid 26324100)
15. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82. (Pubitemid 27441162)
16. Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000;165:2651-6. (Pubitemid 30660713)
17. Shibata S, Okano S, Yonemitsu Y, Onimaru M, Sata S, Nagata- Takeshita H, et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol 2006;177:3564-76. (Pubitemid 44359887)
18. Krishnan L, Sad S, Patel GB, Sprott GD. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Cancer Res 2003;63:2526-34. (Pubitemid 36605193)
19. Brinkman M, Walter J, Grein S, Thies MJ, Schulz TW, Herrmann M, et al. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma. Cancer Immunol Immunother 2005;54:611-22. (Pubitemid 40603199)
20. Lasarte JJ, Casares N, Gorraiz M, Hervás-Stubbs S, Arribillaga L, Mansilla C, et al. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol 2007;178:748-56. (Pubitemid 46098855)
21. Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, et al. Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 2009; 125:2614-23.
22. Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology 2001;102:486-97. (Pubitemid 32322961)
23. Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007;81:3662-6. (Pubitemid 46456678)
24. Scarlett UK, Cubillos-Ruiz JR, Nesbeth YC, Martinez DG, Engle X, Gewirtz AT, et al. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res 2009;69: 7329-37.
25. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8. (Pubitemid 33009951)
26. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200. (Pubitemid 34141451)
27. Vidalain PO, Azocar O, Servet-Delprat C, Rabourdin-Combe C, Gerlier D, Manie S. CD40 signaling in human dendritic cells is initiated within membrane rafts. Embo J 2000;19:3304-13. (Pubitemid 30428208)
28. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-3. (Pubitemid 36927946)
29. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996;93:4102-7. (Pubitemid 26144250)
30. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virusspecific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998;187:1647-57. (Pubitemid 28235106)
31. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999;162:2227-34. (Pubitemid 29288845)
32. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94. (Pubitemid 29035425)
33. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010;120:607-16.
34. Oh S, Perera LP, Burke DS, Waldmann TA, Berzofsky JA. IL-15/IL- 15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A 2004;101:15154-9. (Pubitemid 39391734)
35. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007;13:843-50. (Pubitemid 47038186)
36. Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007;81:8468-76. (Pubitemid 47242819)
37. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006;107:4781-9. (Pubitemid 43882629)
38. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV- 1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004;103:966-72. (Pubitemid 38129558)
39. Imai N, Ikeda H, Tawara I, Shiku H. Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur J Immunol 2009;39:241-53.